ArticleBMC musculoskeletal disorders2026
Analysis of the efficacy of autologous adipose-derived stromal vascular fraction and calcium phosphate bone cement combined with core decompression in patients with femoral head necrosis: a retrospective study.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundOsteonecrosis of the femoral head (ONFH) is a progressive disorder characterized by impaired perfusion, inflammation, neural dysregulation, and structural failure of the femoral head. While core decompression (CD) is commonly used for joint preservation, its effectiveness remains limited, particularly in the absence of adequate structural support and biological modulation. Adipose-derived stromal vascular fraction (SVF) has emerged as a potential biological adjunct due to its angiogenic, immunomodulatory, and regenerative properties. This study aimed to evaluate the clinical outcomes of combining autologous SVF and calcium phosphate cement (CPC) with CD in patients with ONFH.
methodsWe retrospectively analyzed 148 patients (219 hips) with ONFH treated between 2009 and 2022. Eighty-five hips underwent CD alone (CD group), and 134 hips received SVF combined with CPC and CD (SVF + CPC + CD group). Radiographic progression and conversion to total hip arthroplasty (THA) were assessed according to the Association Research Circulation Osseous (ARCO) staging system. Hip survival was evaluated using Kaplan–Meier analysis, and multivariable Cox proportional hazards regression was performed to identify factors associated with conversion to THA. Clinical outcomes were assessed using the Harris Hip Score (HHS), visual analogue scale (VAS), and the 36-Item Short Form Health Survey (SF-36).
resultsThe SVF + CPC + CD group demonstrated significantly lower radiographic progression (33.6% vs. 55.3%, P < 0.001) and THA conversion rates (20.1% vs. 35.3%, P = 0.013) compared with the CD group. Kaplan–Meier analysis showed superior THA-free survival in the SVF + CPC + CD group. In multivariable Cox regression analysis, treatment with SVF + CPC + CD was independently associated with a reduced risk of conversion to THA, whereas higher ARCO stage was associated with increased failure risk. Smoking status showed a borderline association with THA conversion. At final follow-up, patients treated with SVF + CPC + CD reported lower pain scores, improved hip function, and better outcomes in selected quality-of-life domains compared with CD alone (all P < 0.05).
conclusionIn this retrospective cohort, combining core decompression with structural augmentation and biological modulation using SVF and CPC was associated with improved mid-term radiographic and clinical outcomes compared with CD alone. These findings suggest that an integrated mechanical–biological strategy may offer advantages for hip preservation in selected patients with ONFH; however, prospective randomized studies with longer follow-up are required to confirm efficacy and define optimal indications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.